The IPO market closed out June with four deals, three of which raised $100+ million. In the pipeline, nine companies submitted initial filings, led by what could be the largest IPO of 2024 to date. Web comic platform WEBTOON Entertainment (WBTN) led the week&...read more
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, raised $210 million by offering 13.1 million shares at $16, the low end of the range of $16 to $18. The company offered 4.5 million fewer shares than anticipated. Alumis ...read more
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $300 million by offering 17.7 million shares at a price range of $16 to...read more
Updated Monday, 6/24. Four IPOs are currently scheduled to debut in the week ahead as the second quarter comes to a close. Immunology biotech Alumis (ALMS) plans to raise $300 million at a $1.0 billion market cap. The company is initially focused on...read more
US IPO Weekly Recap: 2Q IPO market closes out with sizable pricings and pipeline additions
The IPO market closed out June with four deals, three of which raised $100+ million. In the pipeline, nine companies submitted initial filings, led by what could be the largest IPO of 2024 to date. Web comic platform WEBTOON Entertainment (WBTN) led the week&...read more
Immunology biotech Alumis prices downsized IPO at $16, the low end of the range
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, raised $210 million by offering 13.1 million shares at $16, the low end of the range of $16 to $18. The company offered 4.5 million fewer shares than anticipated. Alumis ...read more
Immunology biotech Alumis sets terms for $300 million IPO
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $300 million by offering 17.7 million shares at a price range of $16 to...read more
US IPO Week Ahead: Carve-outs, cross-listings, and energy plays close out the 2Q IPO market
Updated Monday, 6/24. Four IPOs are currently scheduled to debut in the week ahead as the second quarter comes to a close. Immunology biotech Alumis (ALMS) plans to raise $300 million at a $1.0 billion market cap. The company is initially focused on...read more